IP Library Granted Patent US 12,522,573
Granted Patent B2
US 12,522,573 · App. 18/032,601 · Granted Jan 13, 2026

Process for preparation of tafamidis and salts thereof

Inventors: Venkata Raghavendra Charyulu Palle (Pune, IN); Suresh Mahadev Kadam (Thane, IN); Vishweshwar Peddy (Hyderabad, IN); Santosh Ramesh Badgujar (Dombivali-West, IN); Vinayak Kacheshwar Bhujade (Ahmednagar, IN); Yogesh Eknath Gagare (Dombivali, IN)
Assignee: ALIVUS LIFE SCIENCES LIMITED
C07D263/57C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,522,573
App. No.
18/032,601
Granted
Jan 13, 2026
Kind
B2
Abstract

The present invention relates to process for preparation of crystalline Form 4 of tafamidis. The present invention also relates to salts of tafamidis and process of preparation of salts of tafamidis. The present invention also relates to process for preparation of an amorphous solid dispersion of tafamidis or salt thereof.

Claims (26)

1 . A process for the preparation of crystalline Form 4 of tafamidis, the process comprising:

(a) providing a solution of tafamidis in a solvent selected from the group consisting of C 1 -C 4 amides, C 2 -C 3 sulfoxides, C 5 -C 6 pyrrolidones, and mixtures thereof; and

(b) obtaining a crystalline Form 4 of tafamidis from the solution of step (a) by:

(i) combining the solution of step (a) with an anti-solvent selected from the group consisting of C 1 -C 8 alcohols, C 3 -C 10 ketones, C 1 -C 3 nitriles, water and mixtures thereof; or

(ii) removing the solvent from the solution of step (a),

wherein the crystalline Form 4 of tafamidis is characterized by an X-ray powder diffraction (XRPD) pattern as illustrated in FIG. 1 .

2 . The process of claim 1 , wherein the step (a) of providing the solution of tafamidis comprises reacting 4-(3,5-dichlorobenzamido)-3-hydroxybenzoic acid with a coupling agent in the solvent to obtain tafamidis, wherein the coupling agent is methanesulfonic acid.

3 . The process of claim 1 , wherein the step (a) of providing the solution of tafamidis comprises reacting a salt of tafamidis with an acid to obtain tafamidis.

4 . The process of claim 2 , wherein the solvent comprises an amide solvent selected from C 1 -C 4 amides.

5 . The process of claim 4 , wherein the amide solvent is one or more of dimethylacetamide and dimethylformamide.

6 . The process of claim 3 , wherein the salt of tafamidis is a morpholine salt of tafamidis.

7 . The process of claim 1 , wherein the crystalline Form 4 of tafamidis obtained in step (b) contains less than about 0.5% w/w of crystalline Form 1 of tafamidis.

8 . A process for the preparation of a salt of tafamidis, the process comprising:

(a) reacting tafamidis with an inorganic base or an organic base to form a reaction mixture comprising the tafamidis salt; and

(b) separating the tafamidis salt from the reaction mixture of the step (a),

wherein the tafamidis of step (a) is obtained by reacting 4-(3,5-dichlorobenzamido)-3-hydroxybenzoic acid with methanesulfonic acid in an amide solvent.

9 . The process of claim 8 , further comprising the step of converting the obtained tafamidis salt to tafamidis comprising:

(a) treating the tafamidis salt with an acid to obtain a reaction mixture; and

(b) separating and isolating the tafamidis obtained in step (a),

wherein the tafamidis obtained is amorphous or crystalline.

10 . The process of claim 8 , wherein the amide solvent is selected from C 1 -C 4 amides.

11 . The process of claim 8 , wherein the tafamidis obtained is not isolated from the reaction mixture and is reacted with the inorganic base or the organic base to form the tafamidis salt.

12 . The process of claim 11 , wherein the organic base is morpholine.

13 . The process of claim 8 , wherein the tafamidis obtained from the reaction mixture is crystalline Form 4 of tafamidis by any one of the following:

(i) combining the reaction mixture with an alcohol, water or mixture thereof; or

(ii) removing the amide solvent from the reaction mixture.

Assignments (2)
CHANGE OF NAME Recorded Jan 7, 2025
From: GLENMARK LIFE SCIENCES LIMITED
To: ALIVUS LIFE SCIENCES LIMITED
Reel/Frame 069775/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2024
From: PALLE, VENKATA RAGHAVENDRA CHARYULU; KADAM, SURESH MAHADEV; PEDDY, VISHWESHWAR; BADGUJAR, SANTOSH RAMESH; BHUJADE, VINAYAK KACHESHWAR; GAGARE, YOGESH EKNATH
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 069705/0643 →
Priority Claims (3)
IN 202021045429 · Oct 19, 2020 · national
IN 202121004662 · Feb 3, 2021 · national
IN 202121011884 · Mar 19, 2021 · national
Continuity (1)
Related Publication 20230391737A1 · Dec 7, 2023
References Cited (4)
WO WO2016038500A1 · 2016 [cited by examiner]
WO WO2017190682A1 · 2017 [cited by examiner]
WO 2019175263A1 · 2019 [cited by applicant]
Mino R. Caira, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, Jan. 1, 1998, pp. 163-208, vol. 198. [cited by applicant]